Forty Seven Inc (FTSV):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Forty Seven Inc (FTSV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11063
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:33
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Forty Seven Inc (Forty Seven), formerly CD47 Sciences Inc is a clinical-stage immuno-oncology company that focuses on the development of therapies to treat cancer. The company’s lead molecule Hu5F9-G4 is a monoclonal antibody that is used against the CD47 receptor. Its monoclonal antibody is evaluated in four phase 1 clinical studies in patients with solid tumors or cutaneous T-cell lymphoma, acute myeloid leukemia, non-Hodgkin’s lymphoma, myelodysplastic syndrome and colorectal carcinoma across the US and the UK. The company partners with biotechnology and pharmaceutical companies. Forty Seven is headquartered in Menlo Park, California, the US.

Forty Seven Inc (FTSV) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Forty Seven Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Forty Seven Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Forty Seven Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Forty Seven Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Forty Seven Inc, Medical Devices Deals, 2012 to YTD 2018 9
Forty Seven Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Forty Seven Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Forty Seven Acquires Assets from BliNK Biomedical 11
Venture Financing 12
Forty Seven Raises USD75 Million in Series B Financing 12
Forty Seven Raises USD75 Million in Series A Venture Financing 13
Partnerships 15
Forty Seven Enters into Agreement with Merck 15
Forty Seven Enters into Agreement with Genentech 16
Licensing Agreements 17
Forty Seven Enters into Licensing Agreement with Stanford University 17
Equity Offering 18
Forty Seven Prices IPO of Shares for USD112.5 Million 18
Forty Seven Inc – Key Competitors 20
Forty Seven Inc – Key Employees 21
Forty Seven Inc – Locations And Subsidiaries 22
Head Office 22
Recent Developments 23
Financial Announcements 23
Nov 13, 2018: Forty Seven reports third quarter 2018 financial results and recent business highlights 23
Aug 13, 2018: Forty Seven reports second quarter 2018 financial results and recent business highlights 25
Corporate Communications 27
Apr 30, 2018: Forty Seven Names Ian T. Clark As Board Director 27
Apr 03, 2018: Forty Seven Appoints Ann D. Rhoads as Chief Financial Officer 28
Feb 20, 2018: Forty Seven Appoints Kristine M. Ball to Board of Directors 29
Mar 20, 2017: Forty Seven Announces Mark McCamish, M.D., Ph.D., to Join as CEO on May 1st 30
Product News 31
12/06/2017: Forty Seven Receives $5 Million Grant from The California Institute for Regenerative Medicine (CIRM) to Support Ongoing Clinical Trial in Acute Myeloid Leukemia 31
04/05/2017: The Leukemia & Lymphoma Society Expands its Innovative Therapy Acceleration Program with a Novel Immunotherapy for Lymphoma Patients 32
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33

List of Tables
Forty Seven Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Forty Seven Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Forty Seven Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Forty Seven Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Forty Seven Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Forty Seven Inc, Medical Devices Deals, 2012 to YTD 2018 9
Forty Seven Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Forty Seven Acquires Assets from BliNK Biomedical 11
Forty Seven Raises USD75 Million in Series B Financing 12
Forty Seven Raises USD75 Million in Series A Venture Financing 13
Forty Seven Enters into Agreement with Merck 15
Forty Seven Enters into Agreement with Genentech 16
Forty Seven Enters into Licensing Agreement with Stanford University 17
Forty Seven Prices IPO of Shares for USD112.5 Million 18
Forty Seven Inc, Key Competitors 20
Forty Seven Inc, Key Employees 21

List of Figures
Forty Seven Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Forty Seven Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Forty Seven Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Forty Seven Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Forty Seven Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Forty Seven Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Forty Seven Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Forty Seven Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Forty Seven Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Forty Seven Inc (FTSV):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Excelsior Gold Limited (EXG):企業の財務・戦略的SWOT分析
    Excelsior Gold Limited (EXG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • CaroGen Corp-製薬・医療分野:企業M&A・提携分析
    Summary CaroGen Corp (CaroGen) is a vaccine company that offers platform technology development services. The company develops and commercializes nanoparticle therapeutic vaccines. It utilizes its virus-like vesicle platform technology, a proprietary replication competent to develop nano particle th …
  • Ishida Co., Ltd.:企業の戦略・SWOT・財務情報
    Ishida Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Ishida Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Yamana Gold Inc.:企業の戦略・SWOT・財務情報
    Yamana Gold Inc. - Strategy, SWOT and Corporate Finance Report Summary Yamana Gold Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Shalimar Paints Ltd (SHALPAINTS):企業の財務・戦略的SWOT分析
    Shalimar Paints Ltd (SHALPAINTS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • New Jersey Resources Corp (NJR):石油・ガス:M&Aディール及び事業提携情報
    Summary New Jersey Resources Corp (NJR) is a provider of natural gas delivery and energy services. The company offers services such as energy services, home services, energy management services and storage facilities. Its home services include home heating services, home AC services, electrical serv …
  • Alten SA:企業の戦略・SWOT・財務情報
    Alten SA - Strategy, SWOT and Corporate Finance Report Summary Alten SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Petroleo Brasileiro SA (PETR4)-石油・ガス分野:企業M&A・提携分析
    Summary Petroleo Brasileiro S.A. (Petrobras) is an integrated oil and gas company. Its major businesses include exploration and production, refining, marketing , trade and transportation of oil and gas. The company also conducts biofuel, petrochemical, natural gas, electricity and chemical-gas busin …
  • Reyes Holdings LLC:企業の戦略的SWOT分析
    Reyes Holdings LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Patria Oyj:企業の戦略・SWOT・財務情報
    Patria Oyj - Strategy, SWOT and Corporate Finance Report Summary Patria Oyj - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Cost Plus Inc:企業の戦略的SWOT分析
    Cost Plus Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • The Parkinson’s Institute and Clinical Center:製薬・医療:M&Aディール及び事業提携情報
    Summary The Parkinson's Institute and Clinical Center (PICC) is a non-profit organization that offers basic and clinical research, clinical trials and patient care services for parkinson’s disease and neurological movement disorders. The organization discovers and develops new treatments to improve …
  • Triple Energy Ltd (TNP):石油・ガス:M&Aディール及び事業提携情報
    Summary Triple Energy Ltd (Triple Energy) is an oil and gas company that explores for natural resources. The company invests in oil and gas projects in the conventional and unconventional sectors such as coal seam gas and shale oil and gas, along with power generation. It offers project such as CFT …
  • Sigma-Tau HealthScience USA, Inc:企業の戦略・SWOT・財務情報
    Sigma-Tau HealthScience USA, Inc - Strategy, SWOT and Corporate Finance Report Summary Sigma-Tau HealthScience USA, Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • UMN Pharma Inc (4585):製薬・医療:M&Aディール及び事業提携情報
    Summary UMN Pharma Inc (UMN Pharma) is a biopharmaceutical company that manufactures therapeutic for muscular dystrophy, diabetes and influenza. The company’s products include UMN-0501, UMN-0502, UMN-2003, UMN-0901 and UMN-2002, among others. Its UMN-0502 is a seasonal influenza vaccine. UMN Pharma’ …
  • VIDA Diagnostics Inc:医療機器:M&Aディール及び事業提携情報
    Summary VIDA Diagnostics Inc (VIDA) is a medical technology company that provides clinical imaging software and analysis services for early detection, evaluation, and treatment of pulmonary diseases. The company offers VIDA exchange and VIDA vision. Its products are used in airway mapping, lung volu …
  • Teva Pharmaceutical Industries Ltd (TEVA):医療機器:M&Aディール及び事業提携情報
    Summary Teva Pharmaceutical Industries Ltd (Teva) is a pharmaceutical company that carries out the research, development, manufacture and commercialization of generic and specialty medicines. It provides specialty medicines to treat disorders of the central nervous system (CNS), respiratory, cancer, …
  • Houlihan Lokey Inc (HLI):企業の財務・戦略的SWOT分析
    Summary Houlihan Lokey Inc (Houlihan) is an investment bank. It provides corporate finance, financial advisory, financial restructuring and strategic consulting services. The bank’s corporate finance services include mergers and acquisitions, capital markets, private fund advisory and board advisory …
  • Simulations Plus Inc (SLP):企業の財務・戦略的SWOT分析
    Simulations Plus Inc (SLP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Cytox Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Cytox Ltd (Cytox) is a diagnostic and prognostic service provider that develops services for neurodegenerative disorders. The company’s blood tests are used to predict, which patients with MCI will develop Alzheimer's disease. Its biomarkers are based on the cell cycle hypothesis of Alzheime …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆